Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
The antibody-drug conjugate shrank tumors in 28% of people with locally advanced or metastatic urothelial cancer.
The antibody-drug conjugate extended survival by four months compared with chemotherapy.
Among urothelial cancer patients treated with atezolizumab, those who used PPIs had a 68 percent greater risk of death.
The immunotherapy is now approved for people whose cancer has not progressed on platinum-based chemotherapy.
These are the latest cancer treatments approved by the FDA.
“Potentially practice-changing” data show patients with advanced urothelial carcinoma survive longer with immune-boosting drug after chemo.
More than half of patients treated with mitomycin experienced complete tumor remission.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.